Predictive value of serum IgE levels during rush hyposensitization

Area of Science:

• Allergy and Immunology
• Pediatric Medicine
• Immunotherapy

Background:

• Hay fever (allergic rhinitis) affects many children, impacting their quality of life.
• Rush hyposensitization is a rapid immunotherapy approach for allergic conditions.
• Predicting the efficacy of immunotherapy is crucial for patient management.

Purpose of the Study:

• To evaluate the predictive value of serum immunoglobulin E (IgE) levels during rush hyposensitization for Timothy pollen allergy in children.
• To identify early indicators of successful immunotherapy outcomes.

Main Methods:

• Studied 30 children with hay fever undergoing rush hyposensitization with Timothy pollen.
• Clinical assessments using diaries over three seasons post-therapy.
• Measured serum IgE levels before and one week after initiating immunotherapy.
• In vivo and in vitro tests, including skin and provocation tests, and Timothy-specific IgG/IgE antibodies were assessed.

Main Results:

• A serum IgE increase >10% in the first week correlated with symptom alleviation in subsequent seasons.
• Children with decreasing or unchanged IgE levels rarely experienced symptom relief.
• Skin tests, provocation tests, and specific IgG/IgE antibodies did not predict clinical response.

Conclusions:

• Serum IgE level monitoring 1 week after initiating rush hyposensitization can predict treatment success in pediatric hay fever.
• This early IgE marker aids in identifying patients likely to benefit from immunotherapy, allowing for timely adjustments.
• Routine IgE measurement is proposed before and after the first week of rush immunotherapy to detect probable therapeutic failures.